Institutional members access full text with Ovid®

Share this article on:

Should the Cost of Care For Patients With Glioblastoma Influence Treatment Decisions?

Dropcho, Edward J. MD

CONTINUUM: Lifelong Learning in Neurology: April 2012 - Volume 18 - Issue 2, Neuro-oncology - p 416–420
doi: 10.1212/01.CON.0000413667.65668.ae
Ethical Perspectives

This article presents the case of a patient with recurrent glioblastoma who questions whether he can or should pay for treatment with bevacizumab. There are differing views on the physician’s role in dealing with cost and cost-effectiveness issues for patients, but it is becoming increasingly unrealistic for physicians to disregard the cost of cancer care when making treatment recommendations. Physicians need to be able to address cost issues in order to allow individual patients to make the best informed decision about what treatment option is the most beneficial and the “best value” for them.

Address correspondence to Dr Edward Dropcho, Indiana University Medical Center, 541 Clinical Drive, Department of Neurology, CL 292, Indianapolis IN 46202, edropcho@iupui.edu.

Relationship Disclosure: Dr Dropcho has served as a speaker for Merck and Co., Inc. and is a member of the editorial board for Medlink Neurology.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Dropcho reports no disclosure.

© 2012 American Academy of Neurology
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website